Anti-HER2 CAR-T cells evaluation in a ovarian tumor preclinical model

Aragao, Emmanuel Arthur Albuquerque; Abdo, Luiza de Macedo; Mannarino, Eduardo; Vieira, Layla; Reis, Sabrina; Hajdu, Karina; Ribeiro, Leandro; Bonamino, Martín.
No convencional en Inglés | ARCA | ID: arc-58001

Documentos relacionados

  1. Association of HER2 codon 655 polymorphism with ovarian cancer.
  2. [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas].
  3. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.
  4. The Her2 gene aberrations in mucinous ovarian carcinoma: Analysis of twenty-one cases.
  5. Both <i>Kras</i> gene mutation and <i>Her2</i> gene mutation tend to exist in an inverse manner but not mutually exclusive in mucinous ovarian carcinoma: An analysis of 21 taiwanese women.
  6. Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study.
  7. Locally produced autoantibodies in cancer.
  8. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors.
  9. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
  10. Is Her-2/neu expressed in nonepithelial ovarian malignancies?